Gilead Sciences, Inc. Announces 24-Week Results from Phase II Study of Investigational HIV Integrase Inhibitor GS 9137

LOS ANGELES--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) today announced 24-week data from a Phase II clinical trial evaluating three doses of GS 9137 (elvitegravir), a novel oral HIV integrase inhibitor. The data, presented this week at the 14th Conference on Retroviruses and Opportunistic Infections (CROI) by Andrew Zolopa, MD, Associate Professor, Stanford School of Medicine (Abstract #J-1007, Late Breaker #143LB), show statistically superior reductions in viral load among HIV-positive treatment-experienced patients receiving 125 mg of once-daily GS 9137 boosted with 100 mg of ritonavir, compared to those receiving a boosted protease inhibitor, both in combination with an optimized background regimen.

MORE ON THIS TOPIC